Kazia Therapeutics Ltd ADR (KZIA) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous...
Analysis Summary
Kazia Therapeutics Ltd ADR reported revenue of $42000 in the most recent fiscal year, growing at a 5-year CAGR of -46.8%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -920.9%, net margin -1130.0%.
At the current price of $10.20, KZIA has negative trailing earnings (P/E not meaningful) and an ROE of -116.86%. Market capitalisation stands at $17M.
Balance sheet quality for KZIA: current ratio of 0.4, net cash position of $3.9M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $10.20 |
| Market Cap | $17M |
| Exchange | NASDAQ |
| Country | AU |
Valuation Ratios
| Price / Book | 0.95 |
| EV / EBITDA | 2.30 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -116.86% |
| Return on Invested Capital | -36.21% |
| Return on Assets | -31.35% |
| Gross Margin | 100.00% |
| Operating Margin | -92086.45% |
| Net Margin | -113004.58% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 2.87 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -40.25 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| KZIA | Kazia Therapeutics Ltd ADR | $17M | 0.95 | -116.9% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -29.07% |
| 3 months | -26.41% |
| Year-to-date | +48.04% |
| 1 year | +28.46% |
| 3 years | -79.60% |
| 5 years | -98.12% |
52-Week Range
| 52-week High | $17.40 |
| 52-week Low | $4.86 |
| Avg Volume (90d) | 230K |
Related companies: BDRX · CANF · CMND · CNSP · GRI · INM · OGEN
Explore sector: Healthcare · Biotechnology
More sections of KZIA: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks